Evidence map›Paper›PMID 28217866›Full record

ReviewBritish journal of pharmacology2017

Zebrafish models in neuropsychopharmacology and CNS drug discovery.

Kanza M Khan, Adam D Collier, Darya A Meshalkina, Elana V Kysil, Sergey L Khatsko, Tatyana Kolesnikova, Yury Yu Morzherin, Jason E Warnick, Allan V Kalueff, David J Echevarria

Open access · bronzeAbstract readReview
In one paragraph

Review in British journal of pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 193 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Unravelling the developmental toxicity of heavy metals using zebrafish as a model: a narrative review.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2025
    Review
  16. Review
  17. Article
  18. Analysis of the underlying mechanism ofPharmaceutical science advances · 2024
    Article
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Kanza M KhanDepartment of Psychology, University of Southern Mississippi, Hattiesburg, MS, USA.
Adam D CollierDepartment of Psychology, University of Southern Mississippi, Hattiesburg, MS, USA.
Darya A MeshalkinaThe International Zebrafish Neuroscience Research Consortium (ZNRC), Slidell, LA, USA.
Elana V KysilInstitute of Translational Biomedicine, St. Petersburg State University, St. Petersburg, Russia.
Sergey L KhatskoUral Federal University, Ekaterinburg, Russia.ORCID 0000-0001-5921-6680
Tatyana KolesnikovaUral Federal University, Ekaterinburg, Russia.
Yury Yu MorzherinUral Federal University, Ekaterinburg, Russia.ORCID 0000-0002-1333-6676
Jason E WarnickThe International Zebrafish Neuroscience Research Consortium (ZNRC), Slidell, LA, USA.
Allan V KalueffThe International Zebrafish Neuroscience Research Consortium (ZNRC), Slidell, LA, USA.
David J EchevarriaDepartment of Psychology, University of Southern Mississippi, Hattiesburg, MS, USA.
Ural Federal University · RUClinical Research Consortium · USSt Petersburg University · RUUniversity of Southern Mississippi · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the high prevalence of neuropsychiatric disorders, their aetiology and molecular mechanisms remain poorly understood. The zebrafish (Danio rerio) is increasingly utilized as a powerful animal model in neuropharmacology research and in vivo drug screening. Collectively, this makes zebrafish a useful tool for drug discovery and the identification of disordered molecular pathways. Here, we discuss zebrafish models of selected human neuropsychiatric disorders and drug-induced phenotypes. As well as covering a broad range of brain disorders (from anxiety and psychoses to neurodegeneration), we also summarize recent developments in zebrafish genetics and small molecule screening, which markedly enhance the disease modelling and the discovery of novel drug targets.

Indexed as

Disease Models, AnimalDrug DiscoveryAnimalsCentral Nervous System AgentsCentral Nervous System DiseasesDrug Evaluation, PreclinicalSmall Molecule LibrariesZebrafishCentral Nervous System AgentsSmall Molecule Libraries

Identifiers

PMID28217866
PMCPMC5466539
OpenAlexW2589167692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.